DARE News and Press, Dare Bioscience Inc. From 11/20/23

SAN DIEGO and MORRISVILLE, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Premier Research International, LLC, a global clinical research, product development, and consulting company, today announ...

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, toda...

2023-11-09 21:56:04 ET Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Conference Call November 09, 2023, 04:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Commercial Officer Lisa Walters-Hoffert - CFO Confer...

2023-11-09 08:16:03 ET More on Dare Bioscience Dare Bioscience Q3 2023 Earnings Preview Daré Bioscience's stock rises ~15% on $1.8M milestone from Organon for Xaciato Seeking Alpha’s Quant Rating on Dare Bioscience Historical earnings data for Dar...

Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™ : receipt of $1.8 million triggered by achievement of first commercial milestone under license agreement with Organon Ovaprene® : commencement of pivotal...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Dare Bioscience Inc. (DARE) is expected to report $-0.1 for Q3 2023

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s President and CEO, Sabrina Martucci Johnson, and Medical Advisor Andrew T. Goldstein, MD, will partic...

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 9, 2023, to review its financial results ...

Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual Interest/Arousal Disorder (FSIAD), With Primary Complaint of Arousal Dysfunction Achieved Statistical Significance and Clinically Meaningful Improvement in Phase 2b Co-Primary Endpo...